CTI BioPharma Corp.

2.41-0.0200-0.82%Vol 1.64M1Y Perf 162.02%
Apr 13th, 2021 16:00 DELAYED
BID2.38 ASK2.42
Open2.42 Previous Close2.43
Pre-Market- After-Market2.41
 - -  - -%
Target Price
6.90 
Analyst Rating
— 0.00
Potential %
186.31 
Finscreener Ranking
★★★     50.30
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★     46.58
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
★★     45.55
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap184.82M 
Earnings Rating
Buy
Price Range Ratio 52W %
47.40 
Earnings Date
6th May 2021

Today's Price Range

2.302.44

52W Range

0.86004.13

5 Year PE Ratio Range

-1.30-2.00

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
-7.25%
1 Month
-26.59%
3 Months
-26.36%
6 Months
-21.61%
1 Year
162.02%
3 Years
-37.53%
5 Years
-53.27%
10 Years
-97.87%

TickerPriceChg.Chg.%
CTIC2.41-0.0200-0.82
AAPL134.433.19002.43
GOOG2 267.2712.48000.55
MSFT258.312.40000.94
XOM55.710.21000.38
WFC39.79-0.9800-2.40
JNJ159.48-2.1600-1.34
FB309.76-1.7800-0.57
GE13.44-0.1500-1.10
JPM154.09-1.8600-1.19
Financial StrengthValueIndustryS&P 500US Markets
3.10
3.20
0.02
0.13
-49.80
Leverage Ratio 1.40
ProfitabilityValueIndustryS&P 500US Markets
-
-1 885.30
-1 861.90
-551.90
-
RevenueValueIndustryS&P 500US Markets
0.00
0.00
-54.98
-37.25
Earnings HistoryEstimateReportedSurprise %
Q04 2020-0.16-0.20-25.00
Q03 2020--0.15-
Q02 2020--0.19-
Q01 2020--0.20-
Q04 2019--0.14-
Q03 2019--0.17-
Q04 2016-0.70-0.2367.14
Q03 2016-0.07-0.10-42.86
Earnings Per EndEstimateRevision %Trend
9/2017 QR-0.700.00-
12/2020 QR-0.160.00-
12/2021 FY-0.722.70Positive
12/2022 FY-0.68-17.24Negative
Next Report Date6th May 2021
Estimated EPS Next Report-0.17
Estimates Count1
EPS Growth Next 5 Years %-
Volume Overview
Volume1.64M
Shares Outstanding76.69M
Trades Count6.57K
Dollar Volume2.21M
Avg. Volume928.34K
Avg. Weekly Volume1.49M
Avg. Monthly Volume1.76M
Avg. Quarterly Volume992.69K

CTI BioPharma Corp. (NASDAQ: CTIC) stock closed at 2.43 per share at the end of the most recent trading day (a -5.81% change compared to the prior day closing price) with a volume of 1.15M shares and market capitalization of 184.82M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 25 people. CTI BioPharma Corp. CEO is Adam R. Craig.

The one-year performance of CTI BioPharma Corp. stock is 162.02%, while year-to-date (YTD) performance is -24.53%. CTIC stock has a five-year performance of -53.27%. Its 52-week range is between 0.86 and 4.13, which gives CTIC stock a 52-week price range ratio of 47.40%

CTI BioPharma Corp. currently has a PE ratio of -3.40, a price-to-book (PB) ratio of 5.70, a price-to-sale (PS) ratio of 33.81, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -96.57%, a ROC of -89.91% and a ROE of -159.38%. The company’s profit margin is -%, its EBITDA margin is -1 861.90%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from CTI BioPharma Corp., there were 0 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.17 for the next earnings report. CTI BioPharma Corp.’s next earnings report date is 06th May 2021.

The consensus rating of Wall Street analysts for CTI BioPharma Corp. is (0), with a target price of $6.9, which is +186.31% compared to the current price. The earnings rating for CTI BioPharma Corp. stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

CTI BioPharma Corp. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

CTI BioPharma Corp. has a Sell technical analysis rating based on Technical Indicators (ADX : 11.35, ATR14 : 0.23, CCI20 : -94.86, Chaikin Money Flow : -0.09, MACD : -0.13, Money Flow Index : 24.34, ROC : -13.83, RSI : 43.24, STOCH (14,3) : 6.82, STOCH RSI : 0.61, UO : 36.43, Williams %R : -93.18), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of CTI BioPharma Corp. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
1 (100.00 %)
Moderate Buy
0
0
0 (0.00 %)
Hold
0
0
0 (0.00 %)
Moderate Sell
0
0
0 (0.00 %)
Strong Sell
0
0
0 (0.00 %)
Summary Rating--Strong Buy
1.00

CTI BioPharma Corp.

CTI BioPharma Corp is a biopharmaceutical company focused on the acquisition, development, and commercialization of less toxic and more effective cancer therapies. The company's therapeutic area is blood-related cancers. Its products under pipeline include PIXUVRI, and Pacritinib. PIXUVRI is a novel aza-anthracenedione with unique structural and physiochemical properties. Pacritinib is an investigational oral kinase inhibitor for the treatment of adult patients with myelofibrosis.

CEO: Adam R. Craig

Telephone: +1 206 282-7100

Address: 3101 Western Avenue, Seattle 98121, WA, US

Number of employees: 25

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

52%48%

News

Stocktwits